Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

PRE-CLOSE TRADING STATEMENT

22 Jan 2015 07:00

RNS Number : 8047C
Cello Group plc
22 January 2015
 

FOR IMMEDIATE RELEASE 

22 JANUARY 2015

Cello Group plc

('Cello' or the 'Group')

PRE-CLOSE TRADING STATEMENT

Cello, the health and consumer strategic marketing group, today publishes the following trading update for the year ended 31 December 2014.

The Group has experienced strong trading for the year, with revenues and headline profits in line with consensus market expectations.

Highlights

- Cello Health maintains strong headline revenue growth and 20% operating margins

- Recent investments in iS Healthcare Dynamics and Promedica already bedding in well

- Recent investments in overseas expansion performing to plan

- Good momentum into 2015 from strong bookings in Q4 2014

Cello Health

Cello Health delivered double digit revenue growth, whilst maintaining 20% operating margins. The majority of Cello Health's revenues come from outside the UK, with the US being the primary overseas growth market. The acquisition of iS Healthcare Dynamics in May 2014 has proved a rapid success, reinforcing the global medical communications capability the Group can offer clients. The acquisition of Promedica in December 2014 has given Cello Health a presence on the West Coast of the USA enabling access to existing clients and the large biotech community there.

The integrated proposition and capabilities of Cello Health have resulted in the winning of a number of high profile contracts which the Group would not otherwise have secured. As a consequence, the last quarter of 2014 secured a strong new business pipeline for 2015, providing confidence for the new year. Of particular note is a multi capability contract secured from a major pharmaceutical client which is worth at least $7m a year.

Cello Signal

Full year revenue growth in Cello Signal was achieved across the year, against a tough comparator for the second half of 2013 which was influenced heavily by a one off project at the time.

The rapid transition to a digital product suite included continued investment in Pulsar, which generated an approximately £0.4m headline operating loss for the period on £1.2m of revenues. These revenues continue to grow. The acquisition of Line Digital in May 2014 has bedded in well and been fully integrated with Blonde, Signal's core technology business.

The overseas presence of Signal has been enhanced with new offices in New York, Singapore and Hong Kong, increasing the ability to service global contracts, although reducing operating margins in the short term.

Several large multi-year contracts were secured against global technology competitors, which have confirmed the validity of the growth strategy for Signal.

A restructuring charge of £0.5m has been incurred in the process of continuing the transition of Signal to delivering global technology solutions.

Bookings momentum towards the end of 2014 provides Signal with a solid platform for 2015.

Balance Sheet

Overall cash flow was delivered as planned, accounting for acquisition costs, increases and acceleration of dividend and the anticipated working capital outflow. Net debt at 31 December 2014 was approximately £7.0m, which remains well below 1 times EBITDA.

In 2014 the Group secured an extension of the existing facility with RBS until April 2018, at reduced cost.

VAT issue

Following discussion between HMRC, The Direct Marketing Association and The Charity Tax Group regarding the VAT status of the supply of certain goods and services to charities, one of Cello Signal's subsidiaries, in good faith, may not have been charging VAT on certain items to its charity clients appropriately. The Group intends to robustly defend its historical position on this issue which it believes has been in line with historical industry practice. Any backdated VAT assessment arising would be substantially contractually recoverable from clients should this be appropriate. The Group's current estimate of the maximum potential liability before recovery is between £1m and £2m and a non-headline exceptional charge would be made in the event of a claim. The Group will update on this matter as appropriate.

Outlook

The Group begins the new year with good bookings momentum from the last quarter of 2014 and, at this early stage of the year, the Board is confident of a strong trading year ahead.

Preliminary results

The preliminary results for year ended 31 December 2014 will be announced on 19 March 2015.

 

Enquiries:

Cello Group plc (www.cellogroup.com)

 

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

 

 

 

Cenkos Securities

 

Bobbie Hilliam

020 7484 4040

 

 

Buchanan

 

Mark Edwards, Sophie McNulty, Robbie Ceiriog-Hughes

020 7466 5000

www.buchanan.uk.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPKDDPABKDKDB
Date   Source Headline
17th Mar 20097:00 amRNSFinal Results
26th Feb 20098:00 amRNSNotice of Results
19th Jan 20097:00 amRNSYear end trading update
18th Dec 200812:38 pmRNSKevin Steeds
4th Dec 20087:00 amRNSDirector/PDMR Shareholding
30th Oct 20081:33 pmRNSChange of Adviser Name
16th Sep 20087:00 amRNSInterim Results
2nd Sep 20082:00 pmRNSInterim Board role change
18th Aug 20084:12 pmRNSNotice of Results
18th Aug 20081:13 pmRNSHolding(s) in Company
13th Aug 20082:16 pmRNSHolding(s) in Company
6th Aug 20082:56 pmRNSHolding(s) in Company
4th Jul 20087:00 amRNSHalf year trading update
24th Jun 200810:44 amRNSDirector/PDMR Shareholding
12th Jun 20081:22 pmRNSDirector/PDMR Shareholding
20th May 20081:25 pmRNSAGM Statement
23rd Apr 200812:59 pmRNSAnnual Report & AGM
17th Apr 20087:00 amRNSAdditional Listing / TVR
28th Mar 20086:11 pmRNSAdditional listing / TVR
25th Mar 20084:04 pmRNSDirector/PDMR Shareholding
19th Mar 20088:35 amRNSDirector/PDMR Shareholding
18th Mar 200810:40 amRNSPerformance Share Option Plan
18th Mar 20087:01 amRNSFinal Results
26th Feb 20087:01 amRNSTotal Voting Rights
13th Feb 200811:03 amRNSNotice of Results
17th Jan 200810:53 amRNSTransaction in Own Shares
16th Jan 20083:03 pmRNSDirector/PDMR Shareholding
16th Jan 20082:19 pmRNSTransaction in Own Shares
16th Jan 200810:54 amRNSTransaction in Own Shares
15th Jan 20087:00 amRNSTrading Statement
3rd Jan 20084:56 pmRNSNotification of Interests
21st Dec 20078:05 amRNSChange of Adviser
14th Dec 200711:10 amRNSDirector/PDMR Shareholding
30th Nov 20073:29 pmRNSTotal Voting Rights
24th Oct 20071:30 pmRNSDirector/PDMR Shareholding
24th Oct 20077:00 amRNSPerformance Share Option Plan
23rd Oct 20077:01 amRNSAcquisition
2nd Oct 20079:59 amRNSTransactions in own shares
26th Sep 200711:35 amRNSAdditional Listing
17th Sep 20077:01 amRNSAcquisition
11th Sep 20077:01 amRNSInterim Results
31st Aug 20075:08 pmRNSTVR Update
30th Aug 20079:15 amRNSAdoption of IFRS
20th Aug 20072:53 pmRNSNotice of Results
13th Aug 20074:40 pmRNSRule 26
30th Jul 20071:55 pmRNSAdditional Listing
20th Jul 200710:00 amRNSHolding(s) in Company
12th Jul 20077:00 amRNSTrading Statement
9th Jul 20072:06 pmRNSTotal Voting Rights
6th Jul 20077:01 amRNSAcquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.